CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
我们的工作确立了CD81作为连接放射抵抗与免疫逃逸的关键桥梁,其通过维持GBM中CD274的丰度发挥作用,并突显CD81作为优化放射免疫治疗的有前景的治疗靶点。
英文原题:Engineering Macrophage Exosome Disguised Biodegradable Nanoplatform for Enhanced Sonodynamic Therapy of Glioblastoma.
这些发现表明,CSI@Ex-A可作为GBM治疗的有效纳米平台,具有临床转化潜力。
声动力疗法(SDT)具有高组织穿透性和对正常组织可忽略的辐射损伤,因此成为一种有前景的胶质母细胞瘤(GBM)治疗手段。然而,血脑屏障(BBB)和缺氧微环境极大地限制了SDT效率。在本工作中,通过将过氧化氢酶(CAT)封装到二氧化硅纳米颗粒(CAT@SiO2)中制备了一种可生物降解的纳米平台(称为CSI),用于缓解肿瘤缺氧,然后负载声敏剂吲哚菁绿(ICG)。受巨噬细胞穿越BBB能力的启发,CSI进一步用AS1411适配体修饰的巨噬细胞外泌体包覆,形成CSI@Ex-A,其具有高效的BBB穿透能力和良好的癌细胞靶向能力。肿瘤细胞内吞后,高表达的谷胱甘肽(GSH)触发纳米平台的生物降解,释放的CAT催化过氧化氢(H2O2)产生O2以缓解肿瘤缺氧。GSH耗竭和O2自供给在体外和体内均有效增强了SDT效率。此外,所得的CSI@Ex-A表现出良好的生物相容性和长循环时间。这些发现表明,CSI@Ex-A可作为GBM治疗的有效纳米平台,具有临床转化潜力。
Sonodynamic therapy (SDT) exhibits high tissue penetration and negligible radiation damage to normal tissues, and thus emerges as a promising cancer therapeutic modality for glioblastoma (GBM). However, the blood-brain barrier (BBB) and hypoxic microenvironment greatly limit the SDT efficiency. In this work, a biodegradable nanoplatform (termed as CSI) is fabricated by encapsulating catalase (CAT) into silica nanoparticles (CAT@SiO 2 ) for tumor hypoxia relief, and then loaded with the sonosensitizer indocyanine green (ICG). Inspired by the ability of macrophages to cross the BBB, CSI is further coated with AS1411 aptamer-modified macrophage exosomes to form CSI@Ex-A, which possesses efficient BBB penetration and good cancer-cell-targeting capability. After tumor cell endocytosis, highly expressed glutathione (GSH) triggeres biodegradation of the nanoplatform and the released CAT catalyzes hydrogen peroxide (H 2 O 2 ) to produce O 2 to relieve tumor hypoxia. The GSH depletion and O 2 self-supplying effectively enhances the SDT efficiency both in vitro and in vivo. In addition, the resulting CSI@Ex-A exhibits good biocompatibility and long circulation time. These findings demonstrate that CSI@Ex-A may serve as a competent nanoplatform for GBM therapy, with potential for clinical translation.
MEMBER ACCOUNT
登录成功会直接打开下一页。